[Pubmed] The clinical need for clustered AChR cell-based assay testing of seronegative MG
Posté : 02 avr. 2022 12:00
J Neuroimmunol. 2022 Mar 25;367:577850. doi: 10.1016/j.jneuroim.2022.577850. Online ahead of print.
ABSTRACT
Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acetylcholine receptor (AChR) autoantibodies are detectable by a clustered AChR cell-based assay (CBA). Of 99 SNMG patients from two academic U.S. centers, 18 (18.2%) tested positive by this assay. Autoantibody positivity was further validated in 17/18 patients. In a complementary experiment, circulating AChR-specific B cells were identified in a CBA-positive SNMG patient. These findings corroborate the clinical need for clustered AChR CBA testing when evaluating SNMG patients.
PMID:35366559 | DOI:10.1016/j.jneuroim.2022.577850
Source: https://pubmed.ncbi.nlm.nih.gov/3536655 ... 5&v=2.17.6